Manufacturer positions liraglutide generic as an “affordable” option for the self-pay market
GLP-1 agonists, known as "weight-loss injections," are currently the drug of choice in drug-based obesity therapy. Now, the first representative of this drug class is off-patent.
Arzte zeitung
